MBX Biosciences
IPO
Precision Therapeutics. Simplified Disease Management.
- Employees
- 11–50
- Business Model
- B2B
- Website
- mbxbio.com
- Total Funding
- $113.1M
- Last Round
- $63.5M Series CAug 2024
About
MBX Biosciences is pioneering Precision Endocrine Peptide (PEP) therapeutics for patients with endocrine and metabolic disorders. Its pipeline includes MBX 2109 (Phase 2, hypoparathyroidism), MBX 1416 (Phase 1, post-bariatric hypoglycemia), and pre-clinical obesity programs. The company went public on Nasdaq (MBX) in September 2024.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account